These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3543760)

  • 41. The controversial role of bromocriptine in Parkinson's disease.
    Hardie RJ; Lees AJ; Stern GM
    Clin Neuropharmacol; 1985; 8(2):150-5. PubMed ID: 3891083
    [No Abstract]   [Full Text] [Related]  

  • 42. Editorial: Alternatives to levodopa.
    Br Med J; 1976 May; 1(6019):1169-70. PubMed ID: 1268610
    [No Abstract]   [Full Text] [Related]  

  • 43. The effect of bromocriptine (BCT) on the on-off phenomenon.
    Glantz R; Goetz CG; Nausieda PA; Weiner WJ; Klawans HL
    J Neural Transm; 1981; 52(1-2):41-7. PubMed ID: 7026735
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Parlodel: a new therapeutic possibility in the management of Parkinson disease].
    Glaub T; Berecz G; Pintér N; Diószeghy P; Virga A; Mechler F
    Orv Hetil; 1988 Feb; 129(8):399-402. PubMed ID: 3279375
    [No Abstract]   [Full Text] [Related]  

  • 45. Parkinson's disease: search for better therapies.
    Marx JL
    Science; 1979 Feb; 203(4382):737-8. PubMed ID: 419406
    [No Abstract]   [Full Text] [Related]  

  • 46. Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
    Agnoli A; Ruggieri S; Casacchia M
    Pharmacology; 1978; 16 Suppl 1():174-88. PubMed ID: 347463
    [No Abstract]   [Full Text] [Related]  

  • 47. Letter: Growth-hormone responses in Parkinson's disease.
    Parkes JD; Debono AG; Marsden CD
    Lancet; 1976 Feb; 1(7957):483-4. PubMed ID: 55746
    [No Abstract]   [Full Text] [Related]  

  • 48. Bromocriptine (ParlodelR) in the treatment of Parkinson's disease.
    Molina-Negro P; Grimes JD; Jones MW; Kofman OS; Bouchard S
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):503-8. PubMed ID: 6761765
    [No Abstract]   [Full Text] [Related]  

  • 49. [Bromocriptine and Parkinson's disease].
    Vaskov Z; Milić V
    Vojnosanit Pregl; 1985; 42(2):134-7. PubMed ID: 4024502
    [No Abstract]   [Full Text] [Related]  

  • 50. Pain in Parkinson's disease.
    Schott GD
    Pain; 1985 Aug; 22(4):407-411. PubMed ID: 4047709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early treatment of Parkinson's disease. Open studies are unreliable.
    Myllylä V; Heinonen E
    BMJ; 1994 Jan; 308(6923):272-3. PubMed ID: 8111278
    [No Abstract]   [Full Text] [Related]  

  • 52. Late-stage Parkinson's disease in the Lisbon-Barcelona cohorts: past phenomenology and today's clinical needs.
    Echebarria SG
    J Neurol; 2011 May; 258(5):918-9; author reply 920. PubMed ID: 21082323
    [No Abstract]   [Full Text] [Related]  

  • 53. Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease.
    Okun MS; Lang A; Jankovic J
    Mov Disord; 2010 May; 25(7):961-2; author reply 962-3. PubMed ID: 20461816
    [No Abstract]   [Full Text] [Related]  

  • 54. Concerns expressed about PATH program.
    Moskowitz C; Winfield L
    Nurse Pract; 1989 Nov; 14(11):9. PubMed ID: 2586860
    [No Abstract]   [Full Text] [Related]  

  • 55. Neuromythology IX and DATATOP.
    Neurology; 1991 Oct; 41(10):1703-4. PubMed ID: 1922831
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of Parkinson's disease with L-methionine.
    Smythies JR; Halsey JH
    South Med J; 1984 Dec; 77(12):1577. PubMed ID: 6390701
    [No Abstract]   [Full Text] [Related]  

  • 57. Introducing Clinical Trials Highlights.
    McFarthing K
    J Parkinsons Dis; 2019; 9(1):1-2. PubMed ID: 30741693
    [No Abstract]   [Full Text] [Related]  

  • 58. Patients sought for New Zealand multi-centre Parkinson's disease trial.
    Wallis WE
    N Z Med J; 1987 Jan; 100(816):33. PubMed ID: 3543760
    [No Abstract]   [Full Text] [Related]  

  • 59. A progress report on the New Zealand Multicentre Parkinson's disease trial. A comparison of low-dose treatment with bromocriptine or L-dopa.
    Wallis WE
    Eur Neurol; 1988; 28 Suppl 1():9-10. PubMed ID: 3288479
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
    Factor SA; Weiner WJ
    Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.